Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCV-501 in Elderly Patients With Acute Myeloid Leukemia
NCT01961882Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Oct 2013
- Primary completion
- Nov 2017
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing OCV-501 arm with Placebo arm (2 arms). Primary endpoint: Disease-Free Survival at 2 years. Started Oct 2013; status: completed.
02
Drugs
OCV-501
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01961882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01961882.